@article{afed22cbcab144948ad3a99d58684681,
title = "Brain Shrinkage in Anti-β-Amyloid Alzheimer Trials: Neurodegeneration or Pseudoatrophy?",
author = "Frederik Barkhof and Knopman, \{David S.\}",
note = "Funding Information: F. Barkhof serves on the Data Safety Monitoring Board for Prothena and the A45-AHEAD studies led by ATRI/ACTC, for which he receives personal compensation. He is a steering committee member for Merck, Bayer, and Biogen for which he receives personal compensation. He is a consultant to IXICO, Roche, Celltrion, Rewind Therapeutics and Combinostics for which he receives personal compensation. He is supported by the NIHR biomedical research centre at UCLH. D. Knopman serves on a Data Safety Monitoring Board for the Dominantly Inherited Alzheimer Network Treatment Unit study. He served on a Data Safety monitoring Board for a tau therapeutic for Biogen (until 2021) but received no personal compensation. He is an investigator in clinical trials sponsored by Biogen, Lilly Pharmaceuticals, and the University of Southern California. He has served as a consultant for Roche, Samus Therapeutics, Magellan Health, Biovie, and Alzeca Biosciences but receives no personal compensation. He attended an Eisai advisory board meeting for lecanemab on December 2, 2022, but received no compensation directly or indirectly. He receives funding from the NIH. Go to Neurology.org/N for full disclosures.",
year = "2023",
month = may,
day = "16",
doi = "10.1212/WNL.0000000000207268",
language = "English",
volume = "100",
pages = "941--942",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "20",
}